India Pharma Outlook Team | Wednesday, 04 March 2026
U.S. drugmaker Eli Lilly will continue selling its innovator diabetes and obesity drug at premium prices in India even as the market prepares for the arrival of lower-priced generic drugs. The company says it is not planning price reductions despite the expected entry of competing diabetes treatments over the next few years.
The company recently launched tirzepatide, marketed as Mounjaro, in India for the treatment of type-2 diabetes and obesity treatment. The drug has gained strong interest among physicians and patients because of its clinical effectiveness in controlling blood sugar and aiding weight loss. Eli Lilly believes demand for its branded therapy will remain strong even when generic alternatives eventually enter the market.
Industry experts note that the Indian pharmaceutical market is preparing for a wave of generic versions of semaglutide, another widely used obesity and diabetes drug. As patents expire globally, several Indian pharmaceutical companies are working on their own versions of these GLP-1 therapies. These medicines are expected to be sold at significantly lower prices than the innovator drugs.
Despite this expected competition, Eli Lilly executives say the company will continue to position Mounjaro as a premium product supported by strong clinical data and physician confidence. Winselow Tucker, president and general manager of Eli Lilly India, said the India diabetes market is large enough for both innovator and generic drugs.
India is among the countries with the highest number of diabetes patients, and obesity rates are rising steadily in urban populations. This has increased demand for advanced metabolic treatments, particularly weight-loss drugs that deliver improved glucose control and weight reduction.
Global pharmaceutical companies and Indian drugmakers are investing heavily in this segment as demand grows. However, drug pricing in India remains a major factor in the healthcare system, where many patients pay for treatment out of pocket.
Also Read: NATCO Pharma Introduces Generic Blood Cancer Drug in US Market
While generics are expected to make these therapies more affordable and expand patient access, innovator companies like Eli Lilly are betting that strong clinical outcomes, physician trust and brand recognition will allow their products to retain market share even as lower-priced alternatives enter the market.
